UCB0599

DRUG3 trials

Sponsors

UCB Biopharma SRL, UCB Biopharma S.P.R.L.

Conditions

Early-stage Parkinson's DiseaseHealthy Study ParticipantsParkinson's Disease

Phase 1

A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)

CompletedNCT04875962

UCB Biopharma S.P.R.L.Parkinson's Disease

Start: 2019-05-06End: 2020-02-19Updated: 2021-05-06

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

CompletedNCT05845645

UCB Biopharma SRLHealthy Study Participants

Start: 2023-05-31End: 2024-04-13Updated: 2025-12-22

Phase 2

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

CompletedNCT04658186

UCB Biopharma SRLEarly-stage Parkinson's Disease

Start: 2020-12-30End: 2024-09-06Updated: 2025-10-31

Related Papers

Evaluation and Application of a PET Tracer in Preclinical and Phase 1 Studies to Determine the Brain Biodistribution of Minzasolmin (UCB0599).

2023-12-183 citations

In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease

npj Parkinson s Disease2023-07-1726 citations

Phase 1/1b Studies of <scp>UCB0599</scp>, an Oral Inhibitor of α‐Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease

Movement Disorders2022-08-1250 citations